Vaccine
Advancing a new generation of vaccines
Vaccines represent a key research area for Orexo, and early data highlights the potential of AmorphOX® to enable thermostable, needle-free nasal vaccines. In a proof-of-concept in-vivo study conducted in collaboration with Swedish biotech firm Abera Bioscience, Orexo evaluated the performance of Abera’s mucosal influenza vaccine platform combined with the AmorphOX technology.
The study demonstrated that both liquid and powder intranasal formulations generated strong immune responses, systemic IgG in serum and local IgA in the nose and lungs, with no difference between the two formats. Stability testing further confirmed that the core vaccine component retained functionality after six months across a wide temperature range (–20°C to +40°C), reinforcing the potential for global deployment without refrigeration.
Substance
Powder-based vaccine
Development phase
Preclinical
Temperature stability
Retained structure after processing and after 6 months’ storage at 40°C
Administration
Nasal powder
Leverage established manufacturing processes
Yes
Partnership
Abera Bioscience
Unlocking differentiation through technology
AmorphOX enables the development of powder-based vaccine formulations that eliminate cold-chain requirements, reducing cost and complexity in distribution. This capability means Orexo is well-placed to address critical global needs for accessible and scalable vaccines, particularly in pandemic scenarios.
Looking ahead – expanding strategic opportunities
From a long-term perspective, Orexo sees significant potential for AmorphOX in vaccine development and will continue to collect data to validate its unique advantages. Beyond influenza, Orexo is assessing broader applications of AmorphOX across multiple vaccine platforms to strengthen its position in this critical therapeutic area.
Preclinical PK study
AmorphOX powder vs liquid influenza vaccine
Findings: Proof-of-concept data for nasal powder formulated with AmorphOX shows that both liquid and powder intranasal formulations demonstrated robust immune responses.
